within Pharmacolibrary.Drugs.ATC.L;

model L01FX12
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 1200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0028,
    k12             = 0.38,
    k21             = 0.38
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FX12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tafasitamab is a humanized monoclonal antibody targeting CD19, used in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is FDA approved for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for patients with relapsed or refractory DLBCL receiving tafasitamab intravenously. PK parameters are for adult patients as described in registration trials and FDA/EMA assessment reports.</p><h4>References</h4><ol><li><p>Hoy, SM (2020). Tafasitamab: First Approval. <i>Drugs</i> 80(16) 1731–1737. DOI:<a href=&quot;https://doi.org/10.1007/s40265-020-01405-w&quot;>10.1007/s40265-020-01405-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32946059/&quot;>https://pubmed.ncbi.nlm.nih.gov/32946059</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FX12;
